Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins

Molecular Pharmacology

Volumn 75, Issue 6, 2009, Pages 1317-1324

  Petit Topin, Isabelle ^a,b   Turque, Nathalie ^a   Fagart, Jérôme ^a   Fay, Michel ^a   Ulmann, André ^b   Gainer, Erin ^b   Rafestin Oblin, Marie Edith ^a  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b Laboratoire HRA Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

18 OXO 18 VINYLPROGESTERONE; 19 NORPROGESTERONE; ASPARAGINE; ETHISTERONE; LEVONORGESTREL; METHIONINE; NANDROLONE; NORETHISTERONE; PROGESTERONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LIGAND BINDING; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE;

CELL LINE; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; HUMANS; LEVONORGESTREL; MODELS, MOLECULAR; MUTATION; PROGESTERONE CONGENERS; PROGESTINS; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; RECEPTORS, PROGESTERONE; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 66849084016     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.054312     Document Type: Article

References (32)

1. Allan GF, Leng X, Tsai SY, Weigel NL, Edwards DP, Tsai MJ, and O'Malley BW (1992) Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267:19513-195220.
2. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, et al. (2002) Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93-105. (Pubitemid 34874609)
3. Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH, Pearce KH, Stanley TB, Stewart EL, Trump RP, Willson TM, et al. (2005) A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem 280:31283-31293. (Pubitemid 41291866)
4. Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al. (1998) Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54:905-921. (Pubitemid 28443603)
5. de Wet JR, Wood KV, DeLuca M, Helinski DR, and Subramani S (1987) Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7:725-737. (Pubitemid 17004537)
6. Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D, and Rafestin-Oblin ME (1998) Antagonism in the human mineralocorticoid receptor. EMBO J 17:3317-3325. (Pubitemid 28279506)
7. Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, and Rafestin-Oblin ME (2005) Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 12:554-555. (Pubitemid 43085888)
8. Georgiakaki M, Chabbert-Buffet N, Dasen B, Meduri G, Wenk S, Rajhi L, Amazit L, Chauchereau A, Burger CW, Blok LJ, et al. (2006) Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription. Mol Endocrinol 20:2122-2140. (Pubitemid 44286709)
9. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, and Rafestin-Oblin ME (1999) Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett 464:9-13. (Pubitemid 30009740)
10. Hellal-Levy C, Fagart J, Souque A, Wurtz JM, Moras D, and Rafestin-Oblin ME (2000) Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor. Mol Endocrinol 14:1210-1221. (Pubitemid 32260482)
11. Herbomel P, Bourachot B, and Yaniv M (1984) Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell 39:653-662. (Pubitemid 15198603)
12. Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Crystallogr 26:795-800.
13. Laskowski RA, MacArthur MW, Moss DS, and Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291.
14. Lind U, Greenidge P, Gillner M, Koehler KF, Wright A, and Carlstedt-Duke J (2000) Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem 275:19041-19049. (Pubitemid 30422871)
15. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, et al. (2006) The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 58:782-797.
16. Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, and Williams SP (2004) Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem 47:3381-3387. (Pubitemid 38746089)
17. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83:835-839. (Pubitemid 126663112)
18. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, et al. (2000) Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171.
19. Nagy L and Schwabe JW (2004) Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 29:317-324. (Pubitemid 38968764)
20. Pereira de Jésus-Tran K, Côté PL, Cantin L, Blanchet J, Labrie F, and Breton R (2006) Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 15:987-999.
21. Poujol N, Wurtz JM, Tahiri B, Lumbroso S, Nicolas JC, Moras D, and Sultan C (2000) Specific recognition of androgens by their nuclear receptor. A structure-function study. J Biol Chem 275:24022-24032. (Pubitemid 30624693)
22. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, and Thijssen JH (2003) Classification and pharmacology of progestins. Maturitas 46 (Suppl 1:S7-S16.
23. Sitruk-Ware R (2004) Pharmacological profile of progestins. Maturitas 47:277-283. (Pubitemid 38523308)
24. Sitruk-Ware R (2007) The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception 75 (6 Suppl):S155-S160. (Pubitemid 46770707)
25. Souque A, Fagart J, Couette B, Davioud E, Sobrio F, Marquet A, and Rafestin-Oblin ME (1995) The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Endocrinology 136:5651-5658.
26. Stanczyk FZ (2003) All progestins are not created equal. Steroids 68:879-890. (Pubitemid 37532412)
27. Storoni LC, McCoy AJ, and Read RJ (2004) Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr 60:432-438. (Pubitemid 41087570)
28. Thénot S, Henriquet C, Rochefort H, and Cavaillès V (1997) Differential interaction of nuclear receptors with the putative transcriptional coactivator hTIF1. J Biol Chem 272:12062-12068. (Pubitemid 27202785)
29. Tsai MJ and O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann Rev Biochem 63:451-486. (Pubitemid 24218640)
30. Tuba Z, Bardin CW, Dancsi A, Francsics-Czinege E, Molnár C, Csörgei J, Falkay G, Koide SS, Kumar N, Sundaram K, et al. (2000) Synthesis and biological activity of a new progestogen, 16-methylene-17alpha-hydroxy-18- methyl-19-norpregn-4-ene-3, 20-dione acetate. Steroids 65:266-274. (Pubitemid 30177346)
31. Williams SP and Sigler PB (1998). Atomic structure of progesterone complexed with its receptor. Nature 393:392-396. (Pubitemid 28269716)
32. Zhang Z, Olland AM, Zhu Y, Cohen J, Berrodin T, Chippari S, Appavu C, Li S, Wilhem J, Chopra R, et al. (2005) Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J Biol Chem 280:28468-28475. (Pubitemid 41105746)